These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31462094)

  • 1. Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus: The Role of Protein
    Chen Y; Zhao X; Wu H
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1911-1924. PubMed ID: 31462094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights: A role for O-GlcNAcylation in diabetic complications.
    Peterson SB; Hart GW
    Crit Rev Biochem Mol Biol; 2016; 51(3):150-61. PubMed ID: 26806492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications.
    Qin CX; Sleaby R; Davidoff AJ; Bell JR; De Blasio MJ; Delbridge LM; Chatham JC; Ritchie RH
    Pharmacol Res; 2017 Feb; 116():45-56. PubMed ID: 27988387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.
    Semba RD; Huang H; Lutty GA; Van Eyk JE; Hart GW
    Proteomics Clin Appl; 2014 Apr; 8(3-4):218-31. PubMed ID: 24550151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats.
    Akimoto Y; Hart GW; Wells L; Vosseller K; Yamamoto K; Munetomo E; Ohara-Imaizumi M; Nishiwaki C; Nagamatsu S; Hirano H; Kawakami H
    Glycobiology; 2007 Feb; 17(2):127-40. PubMed ID: 17095531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High glucose induces mitochondrial dysfunction independently of protein O-GlcNAcylation.
    Dassanayaka S; Readnower RD; Salabei JK; Long BW; Aird AL; Zheng YT; Muthusamy S; Facundo HT; Hill BG; Jones SP
    Biochem J; 2015 Apr; 467(1):115-26. PubMed ID: 25627821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-GlcNAc signaling in the cardiovascular system.
    Ngoh GA; Facundo HT; Zafir A; Jones SP
    Circ Res; 2010 Jul; 107(2):171-85. PubMed ID: 20651294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hexosamine signaling pathway: deciphering the "O-GlcNAc code".
    Love DC; Hanover JA
    Sci STKE; 2005 Nov; 2005(312):re13. PubMed ID: 16317114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial Mesenchymal Transition Induces Aberrant Glycosylation through Hexosamine Biosynthetic Pathway Activation.
    Lucena MC; Carvalho-Cruz P; Donadio JL; Oliveira IA; de Queiroz RM; Marinho-Carvalho MM; Sola-Penna M; de Paula IF; Gondim KC; McComb ME; Costello CE; Whelan SA; Todeschini AR; Dias WB
    J Biol Chem; 2016 Jun; 291(25):12917-29. PubMed ID: 27129262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in
    Olson AK; Bouchard B; Zhu WZ; Chatham JC; Des Rosiers C
    J Biol Chem; 2020 Feb; 295(7):2018-2033. PubMed ID: 31915250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of O-linked N-acetylglucosamine in the homeostasis of metabolic organs, and its potential links with diabetes and its complications.
    Morino K; Maegawa H
    J Diabetes Investig; 2021 Feb; 12(2):130-136. PubMed ID: 32654398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart.
    McLarty JL; Marsh SA; Chatham JC
    Life Sci; 2013 Mar; 92(11):621-7. PubMed ID: 22985933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice.
    Marsh SA; Dell'Italia LJ; Chatham JC
    Amino Acids; 2011 Mar; 40(3):819-28. PubMed ID: 20676904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-GlcNAcylation and cardiovascular disease.
    Wright JN; Collins HE; Wende AR; Chatham JC
    Biochem Soc Trans; 2017 Apr; 45(2):545-553. PubMed ID: 28408494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of O-linked N-acetylglucosamine (O-GlcNAc) modification of proteins in diabetic cardiovascular complications.
    Chatham JC; Young ME; Zhang J
    Curr Opin Pharmacol; 2021 Apr; 57():1-12. PubMed ID: 32937226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-GlcNAc modification of nucleocytoplasmic proteins and diabetes.
    Akimoto Y; Hart GW; Hirano H; Kawakami H
    Med Mol Morphol; 2005 Jun; 38(2):84-91. PubMed ID: 15944815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GlcNAc modification, insulin signaling and diabetic complications.
    Issad T; Masson E; Pagesy P
    Diabetes Metab; 2010 Dec; 36(6 Pt 1):423-35. PubMed ID: 21074472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein O-GlcNAcylation in diabetes and diabetic complications.
    Ma J; Hart GW
    Expert Rev Proteomics; 2013 Aug; 10(4):365-80. PubMed ID: 23992419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O-GlcNAc signaling: a metabolic link between diabetes and cancer?
    Slawson C; Copeland RJ; Hart GW
    Trends Biochem Sci; 2010 Oct; 35(10):547-55. PubMed ID: 20466550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.